Alzheimer's & dementia
Par Ferguson EL, Wang J, White JS et 6 autres.
Contenu en anglais
We evaluated the effect of acetylcholinesterase inhibitors (AChEIs) and memantine on non-cognitive outcomes by implementing emulated trials in electronic health records.
Ward réunit ces articles dans la même app que vos cartes et vos questions. Un seul compte gratuit pour Ward, Suture, Osler et Prognia.
Individuals diagnosed with cognitive impairment who initiated AChEIs or memantine were matched to up to five non-initiators. Associations of medication initiation with 11 non-cognitive outcomes were estimated using Cox proportional hazards models. We calculated e-values for each hazard ratio (HR) and compared their magnitude to socioeconomic predictors of memantine and AChEI use in a US-based cohort.
AChEI initiation was associated with nine of 11 adverse outcomes. For example, the HR for antipsychotic use = 1.67 (95% confidence interval [CI]: 1.51 to 1.84) and depression HR = 1.86 (1.67 to 2.06). Results for memantine were similar. E-values varied from 1.45 to 2.11 for memantine and 1.40 to 2.44 for AChEIs. Many potential confounders had odds ratios (ORs) > 1.4 for initiation, including marital status (ORs = 1.36 to 6.67).
Memantine and AChEIs were associated with adverse outcomes, and residual confounding was unlikely to fully account for all the observed associations.
Publié dans Alzheimer's & dementia (New York, N. Y.). Le résumé est reproduit tel qu’il a été publié et reste l’œuvre de ses auteurs ; lisez l’article complet à la source.
Prognia référence cet article à des fins de documentation et de formation. Il ne constitue pas un avis médical. Lisez toujours l’original et suivez les recommandations en vigueur et les protocoles locaux avant d’agir.
